RecruitingPhase 2NCT04647240

MTX-001 for the Treatment of Non-Healing Venous Stasis Ulcers

A Two Part, Randomized Study of MTX-001 for the Treatment of Non-Healing Venous Stasis Ulcers


Sponsor

Merakris Therapeutics

Enrollment

80 participants

Start Date

Feb 26, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

DL-VSU-201 is a randomized, double-blind, placebo-controlled study in subjects with a non-infected venous stasis ulcer (VSU) that has failed to demonstrate improvement after receiving at least 4 weeks of standard, conventional wound therapy to evaluate the efficacy and safety of MTX-001.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called MTX-001 (human amniotic fluid) for people with venous leg ulcer and venous stasis ulcer. The study is currently recruiting participants at 10 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALMTX-001 (human amniotic fluid)

Subcutaneous injection into and/or around wound bed weekly


Locations(11)

Site 02

Tucson, Arizona, United States

Site 9C

Castro Valley, California, United States

Site 03

Fresno, California, United States

Site 9A

San Francisco, California, United States

Site 9B

San Francisco, California, United States

Site 12

Vista, California, United States

Site 13

Tampa, Florida, United States

Site 14

Opelousas, Louisiana, United States

Site 04

New Hyde Park, New York, United States

Site 08

Circleville, Ohio, United States

Site 01

Salem, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04647240


Related Trials